The Times Australia
PR Newswire

.
Times Media

.

Sai Life Sciences announces plans to double headcount and expand capabilities in Manchester, UK

Sai Life Sciences announces plans to double headcount and expand capabilities in Manchester, UK

MANCHESTER, England and HYDERABAD, India, Jan. 28, 2021 /PRNewswire/ -- Sai Life Sciences, one of India's fastest growing Contract Research, Development & Manufacturing Organizations[1] (CRDMOs), today announced plans to double its headcount and expand its suite of technical capabilities at its Manchester site, a centre of excellence for API process and analytical development serving an expanding list of global clients.

Sai Life Sciences announces plans to double headcount and expand capabilities in Manchester, UK Sai Life Sciences announces plans to double headcount and expand capabilities in Manchester, UK

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, "We are truly heartened by our customers' response to our Manchester site. The site serves as a vital bridge to our pilot and manufacturing facilities in India, enabling seamless integration with the rest of our service offerings across the USA and India, spanning the drug discovery, development, and commercialisation continuum. This expansion will further enhance our ability to add value to the NCE pipelines of our customers."

The Sai Life Sciences' Manchester site[2] became fully operational in August 2020, onboarded 24 members of staff and has since delivered multiple projects involving complex chemistry. With a growing interest from customers across the UK, Europe and US, the present expansion involves an increase in capacity from 20 to 75 fume cupboards and an increase in headcount from 24 to 50+ scientists. A further expansion will see the addition of a GMP Kilo Lab later in 2021. The company has recently commenced recruitment for multiple positions[3] across API process and analytical research & development, particle sciences and engineering.

Located in the heart of the Alderley Park life-sciences ecosystem, Sai Life Sciences' Manchester site creates opportunities for UK and EU based pharma companies and biotechs to have easier face-to-face collaboration with its scientists, and to provide easier collaboration with US based clients due to reduced time zone differences. The centre of excellence is well-positioned to provide world-class development, scale-up and technology transfer to the Indian sites as and when required. This new expansion will also add capability in several key areas including process analytical technology (PAT), crystallisation development and physical properties analysis.

Sai Life Sciences is currently amid an organization-wide transformation. It is investing US$150 million during 2019-23, as part of the Sai Nxt[4] initiative, across three core areas – people & culture, processes & automation, infrastructure & scientific capabilities.

About Sai Life Sciences

Sai Life Sciences is a full-service CRO/ CDMO driven by a vision to support the launch of 25 new medicines by 2025.  It works with innovator pharma and biotech companies globally, accelerating the discovery, development, and manufacture of complex small molecules. As a pure-play CRO-CDMO, Sai Life Sciences has served diverse NCE development programs, consistently delivering value based on its quality and responsiveness. Today, it works with 7 of the top 10 large pharma companies, as well as several small and mid-sized pharma & biotech companies. Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments. www.sailife.com[5][6]

Photo: https://mma.prnasia.com/media2/1428651/sai_life_sciences_uk_expansion.jpg?p=medium600Logo: https://mma.prnasia.com/media2/1044186/Sai_Life_Sciences_Logo.jpg?p=medium600[7][8]

 

Read more https://www.prnasia.com/story/archive/3262359_AE62359_0

The Times Features

Will the Wage Price Index growth ease financial pressure for households?

The Wage Price Index’s quarterly increase of 0.8% has been met with mixed reactions. While Australian wages continue to increase, it was the smallest increase in two and a half...

Back-to-School Worries? 70% of Parents Fear Their Kids Aren’t Ready for Day On

Australian parents find themselves confronting a key decision: should they hold back their child on the age border for another year before starting school? Recent research from...

Democratising Property Investment: How MezFi is Opening Doors for Everyday Retail Investors

The launch of MezFi today [Friday 15th November] marks a watershed moment in Australian investment history – not just because we're introducing something entirely new, but becaus...

Game of Influence: How Cricket is Losing Its Global Credibility

be losing its credibility on the global stage. As other sports continue to capture global audiences and inspire unity, cricket finds itself increasingly embroiled in political ...

Amazon Australia and DoorDash announce two-year DashPass offer only for Prime members

New and existing Prime members in Australia can enjoy a two-year membership to DashPass for free, and gain access to AU$0 delivery fees on eligible DoorDash orders New offer co...

6 things to do if your child’s weight is beyond the ideal range – and 1 thing to avoid

One of the more significant challenges we face as parents is making sure our kids are growing at a healthy rate. To manage this, we take them for regular check-ups with our GP...

Business Times

Will the Wage Price Index growth ease financial pressure for hous…

The Wage Price Index’s quarterly increase of 0.8% has been met with mixed reactions. While Australian wages continue to i...

Protecting Your Business from Cyber Threats: The Critical Role of…

In today’s digital world, cybersecurity threats pose a significant risk to businesses of all sizes. A data breach can lead ...

Kyndryl ANZ appoints new Head of Strategic Partnerships and Allia…

Former Head of Marketing to lead and grow Kyndryl’s local channel ecosystem and bolster technological capabilities Kyndr...